The first week of 2026 sets high stakes for cannabis as Congress, the White House, and regulators clash.
Congress is back in session and the first week of 2026 sets high stakes for cannabis. DC has delivered a series of consequential developments for the industry, highlighting growing momentum for reform alongside persistent resistance in Washington which could shape the sector’s trajectory throughout 2026. On Capitol Hill, the U.S. House of Representatives moved quickly to pass an appropriations measure to continue long-standing protections for state medical marijuana programs. The bill maintains language barring the Department of Justice from interfering with state-legal medical cannabis systems, a provision which has been renewed annually for nearly a decade. Notably, the House rejected an effort to include language that would have blocked the federal government from rescheduling marijuana under the Controlled Substances Act.
The House vote was seen as a significant signal to the cannabis industry, which has closely watched congressional maneuvering over federal reform. By allowing the spending bill to advance without restrictions on rescheduling, lawmakers effectively cleared one procedural obstacle to a change that could have sweeping financial and regulatory consequences for cannabis businesses nationwide. The measure now heads to the Senate, where similar provisions have historically received bipartisan support.
These legislative developments come as the executive branch continues to press forward with plans to reschedule marijuana. In late December, President Donald Trump issued an executive order directing the Department of Justice to move marijuana from Schedule I to Schedule III, a classification which would formally recognize its medical use and significantly reduce the tax burden on state-legal cannabis operators by easing Internal Revenue Code Section 280E restrictions.
Despite the executive order, progress has been uneven. House Speaker Mike Johnson of Louisiana has publicly expressed opposition to rescheduling, raising concerns about public health and warning against moving too quickly on cannabis reform. His resistance reflects broader divisions within Congress, particularly among conservative lawmakers who remain skeptical of federal marijuana policy changes even as public support for legalization continues to grow.
Adding to the uncertainty, the Drug Enforcement Administration has indicated it will follow standard administrative procedures before implementing any rescheduling decision. While the White House has called for expedited action, industry observers say the DEA’s internal review process could slow the timeline, potentially pushing final implementation well into the year.
Beyond marijuana itself, federal attention has also turned to hemp and hemp-derived products. Regulatory scrutiny of intoxicating hemp compounds, including delta-8 and similar cannabinoids, remains intense as lawmakers and federal agencies debate tighter limits on THC content and clearer enforcement standards. While recent executive actions did not directly alter existing hemp law, companies across the sector are preparing for potential changes later this year potentially reshaping the rapidly growing hemp marketplace.
Taken together, the opening days of 2026 underscore a cannabis industry navigating a complex policy environment. Congressional support for medical marijuana protections, executive pressure to advance rescheduling, leadership opposition in the House, and unresolved questions around hemp regulation have combined to create a moment of high stakes and mixed signals. How these forces resolve in the coming months will have lasting implications for patients, consumers, investors, and businesses across the United States.
Sara Carter Bailey approved for new drug czar as cannabis rescheduling debates grow amid strong public support and political resistance.
The U.S. cannabis industry stands at an inflection point as federal policy debates over rescheduling marijuana intensify. After decades of cannabis being listed as a Schedule I controlled substance — the federal designation reserved for drugs deemed to have no accepted medical use and a high potential for abuse — recent actions by the executive branch have signaled a willingness to reconsider the status. In 2025, the current president signed an executive order aimed at expediting the rescheduling of cannabis, potentially from Schedule I to Schedule III, a move acknowledging its medical use and ease research and regulatory burdens which have long hampered the industry. This shift has been buoyed by strong public support: polls consistently show a majority of Americans favor federal cannabis reform, even as some political leaders, including House Speaker Mike Johnson, have expressed resistance to broader legalization efforts. Federal rescheduling has become a flashpoint in the ongoing debate about drug policy and states’ rights. And to add something to the mix, Sara Carter Bailey approved for new drug czar, adding another level of unknown.
The U.S. Senate confirmed Bailey on 6 January 2026, as the new Director of the White House Office of National Drug Control Policy (ONDCP), often referred to as the federal “drug czar,” in a 52–48 vote. Her appointment comes at a consequential juncture for national drug policy, including cannabis reform. Bailey’s confirmation marks the first time a woman has led the ONDCP, placing her at the center of efforts to shape how the federal government approaches both illicit substances and regulated medical drugs.
Bailey’s background is unconventional for the post. She built her career as an investigative journalist, covering drug trafficking, national security, and cartel operations, including time as a contributor to national news outlets. She has never before held public office, nor does she have formal training in public health, law enforcement, or drug policy — a point which drew scrutiny from some senators during her confirmation process. Critics questioned her qualifications, while supporters highlighted her on-the-ground reporting experience and understanding of the complex landscape of illegal narcotics.
On issues directly affecting the cannabis industry, Bailey has left a mix of signals. During her confirmation hearing, she described cannabis rescheduling as a “bipartisan issue” and emphasized federal policy should be informed by “research and data” as the administration evaluates next steps. She also acknowledged past public comments supporting medical cannabis, saying she does not “have any problem if it’s legalized and monitored,” particularly for therapeutic use. However, as the incoming head of ONDCP, she has stopped short of advocating specific policy changes, noting her role requires compliance with existing federal law and collaboration with interagency partners.
Industry observers and advocates will be watching closely to see how Bailey’s tenure influences the cannabis sector. Rescheduling to Schedule III could remove significant legal and financial obstacles for medical cannabis businesses, including access to banking services and federal research opportunities. As ONDCP director, Bailey can play a key role in advising the president and shaping the interagency strategy on drug scheduling, public health education, and enforcement — all of which could either accelerate or complicate the pace of federal cannabis reform. Her path forward will require balancing statutory responsibilities with the growing momentum for change among lawmakers, industry stakeholders, and the public.
Ohioans voted to legalize marijuana in 2023 and recreational sales totaled more than $242 million in 2024.
Ohio’s medical marijuana sales started Jan. 14, 2019, and the state’s total medical marijuana sales were $2,293,970,758, as of Jan. 3, according to the Division of Cannabis Control.
Medical marijuana sales brought in more than $233 million in 2025.
Ohio’s average marijuana prices are a bit lower now than they were compared to last year at this time.
The manufactured sales average was $23.83 for the week ending in Jan. 3 compared to $26.66 for the week ending of Jan. 4, 2025, according to the Division of Cannabis Control.
There are 190 dual-use marijuana dispensaries in Ohio, meaning they can sell medical and non-medical marijuana, according to the Division of Cannabis Control.
Ohio Gov. Mike DeWine signed a bill into law last month that made various changes to the state’s voter-passed marijuana law, including adding crimes such as making it illegal to bring legally purchased marijuana from another state back to Ohio.
On the marijuana side, it will reduce the THC levels in adult-use marijuana extracts from a maximum of 90% down to a maximum of 70%, cap THC levels in adult-use flower to 35%, and prohibit smoking in most public places.
The bill gets rid of protections against discrimination for housing, employment, and organ donation. It also allows police to have probable cause during traffic stops if someone is a known user of marijuana.
The bill prohibits possessing marijuana in anything outside of its original packaging and criminalizes bringing legal marijuana from another state back to Ohio. It also requires drivers to store marijuana in the trunk of their car while driving.
The initial signatures were submitted so now Ohio Secretary of State Frank LaRose must verify the signatures and Ohio Attorney General Dave Yost will also have to certify the petition summary is fair and truthful.
If the petition passes those hurdles, organizers can begin canvassing to collect signatures. They’ll need 6% of the total number of votes cast in the most recent gubernatorial election (248,092). The group will also need 3% of an individual county’s gubernatorial turnout in 44 of Ohio’s 88 counties.
Organizers will have 90 days from the date the governor filed the law with the secretary to collect the required signatures.
The last referendum that passed in Ohio was when voters overturned an anti-collective bargaining law in 2011.
Originally published by the Ohio Capital Journal. Republished here with permission.
Learn 3 practical ways to lose weight that actually work including cannabis, focusing on sustainable habits, metabolism, and real-life results.
Losing weight doesn’t require extreme diets, expensive programs, or punishing workout schedules. For most people, the smartest goal is steady, sustainable fat loss—about 1 to 2 pounds per week, which is exactly what most doctors and nutrition experts recommend. Over a month, it adds up to meaningful progress without wrecking your metabolism or daily life.
Here are 3 practical ways to lose weight that actually work including cannabis. No special, expensive tricks but, a proven path a regular person drop pounds safely and consistently, with the third approach highlighting how cannabis can be used thoughtfully as part of a modern wellness strategy.
Weight loss still comes down to one core principle: burning slightly more calories than you consume. The key word is slightly. A daily deficit of 300–500 calories is enough to lose 1–2 pounds per week without triggering intense hunger or fatigue.
The most practical approach:
Focus on protein first (eggs, chicken, fish, beans, Greek yogurt)
Build meals around fiber-rich foods like vegetables, oats, and fruit
Reduce liquid calories such as soda, sweetened coffee, and alcohol
Instead of tracking every bite forever, many people succeed by tracking just two weeks per month to recalibrate portion sizes. This alone often creates the needed calorie deficit.
This approach is simple, flexible, and sustainable for real life.
Photo by Nastasic/Getty Images
You don’t need marathon training to lose weight. Consistency beats intensity every time.
The most effective plan:
30–45 minutes of walking most days of the week
2–3 short strength sessions weekly using bodyweight or light weights
Staying active throughout the day—standing, stretching, and moving often
Walking burns fat efficiently, lowers stress hormones, and is easy to maintain long-term. Strength training preserves muscle mass, which keeps your metabolism higher as you lose weight.
Together, these habits can burn 1,500–2,500 extra calories per week, enough to support steady fat loss without exhaustion.
Cannabis may seem like an unlikely weight-loss tool, but research and real-world use suggest it can play a supportive role when used intentionally.
Many people associate cannabis with overeating, but the reality depends on strain, dosage, and timing.
Smart cannabis use can help by:
Reducing stress and emotional eating
Improving sleep quality, which is crucial for fat loss
Supporting post-workout recovery and pain management
Helping some users regulate appetite more mindfully
Certain strains and cannabinoids, particularly THCV and CBD-dominant products, are associated with appetite control and metabolic balance rather than hunger stimulation.
The most practical approach:
Use low-dose cannabis, not heavy intoxication
Avoid late-night use that leads to snacking
Pair cannabis with healthy routines like walking, stretching, or meal prep
For many adults moving away from alcohol, cannabis can also eliminate hundreds of empty calories per week—often enough on its own to trigger weight loss.
Losing 1–2 pounds per week doesn’t require perfection. It requires small, repeatable habits fitting into daily life.
Control calories without extremes. Move your body consistently. And when used wisely, cannabis can be part of a balanced, modern approach to weight loss and wellness.
Sustainable results don’t come from punishment—they come from smart systems working with your body, not against it
A look at marijuana and Venezuela, including international assessments of drug trafficking, domestic cannabis laws, medical use policies, and public opinion.
The current administration’s seizure of the President and First Lady while taking over of Venezuela has thrust the country into the headlines, especially around drugs and oil. But what is the surprising relationship with Venezuela and marijuana? And there role in the broader context of South America’s illicit drug trade. The country’s actual role is frequently misunderstood. While Venezuela’s geography places it near major drug-producing regions, especially Colombia, recent international assessments suggest its involvement in the global narcotics economy is more limited than commonly portrayed. At the same time, cannabis remains illegal inside Venezuela, with no formal medical marijuana framework and relatively little public debate on legalization.
For decades, Venezuela has been viewed primarily as a transit country rather than a producer of drugs. Its long Caribbean coastline and porous land borders have made it attractive to criminal networks moving cocaine and, to a lesser extent, marijuana out of South America. Marijuana trafficked through Venezuela typically originates in Colombia and is shipped onward to Central America or Caribbean markets. Seizures along border regions and coastal waters have reinforced the country’s reputation as a corridor rather than a source.
The distinction has gained renewed attention following a recent U.S. government report that concluded Venezuela is not among the world’s major players in drug production or large-scale trafficking. The assessment noted Venezuela has no significant coca cultivation and does not rank as a major producer of marijuana. While isolated trafficking networks continue to operate, the report emphasized Venezuela’s overall role in the international drug trade is smaller than several neighboring countries and far from central on a global scale.
Within Venezuela itself, marijuana remains strictly prohibited. Recreational use, cultivation, and distribution are illegal under national law. Possession of small amounts may be treated as personal use, but it can still result in legal consequences, including mandatory rehabilitation or criminal penalties, depending on circumstances and judicial discretion. Law enforcement policy has historically focused on deterrence rather than regulation.
Medical cannabis is also illegal in Venezuela. Unlike many Latin American countries who have introduced tightly controlled medical marijuana programs over the past decade, Venezuela has not adopted legislation allowing cannabis-based treatments. Patients seeking medical cannabis must rely on imported pharmaceuticals which do not contain cannabinoids, or on unregulated alternatives, which remain illegal. Government officials have repeatedly stated cannabis legalization, including for medical purposes, is not currently under consideration.
Public opinion on marijuana use in Venezuela is difficult to measure due to limited polling and the country’s restrictive legal environment. There are no large, nationally representative surveys tracking attitudes toward cannabis legalization or medical use. International studies suggest countries with strict prohibition tend to report lower levels of cannabis use, but Venezuela-specific data remains scarce. Cultural attitudes, legal risk, and limited public discussion all contribute to the absence of reliable usage statistics.
Looking ahead, Venezuela’s cannabis policy appears likely to remain unchanged in the near term. While regional trends point toward broader acceptance of medical marijuana and regulated use elsewhere in Latin America, Venezuela has taken a cautious approach shaped by public security priorities and long-standing drug control laws. As international assessments continue to clarify the country’s limited role in global drug trafficking, future discussion may increasingly focus on domestic health policy and enforcement rather than external perceptions.
What’s next for cannabis in 2026 a look at federal policy, medical research, hemp drinks and state action.
The U.S. cannabis industry enters the new year at a crossroads, shaped by federal policy debates, state-level legislative reviews and growing public acceptance of marijuana as both a consumer product and a medical treatment. While sweeping legalization remains uneven, the year ahead could bring some of the most consequential changes the industry has seen in decades. So what’s next for cannabis in 2026.
At the center of the national conversation is whether marijuana will be rescheduled under federal law. Currently classified as a Schedule I substance — alongside heroin — cannabis is defined as having no accepted medical use. That designation has long conflicted with state medical programs and emerging scientific research.
Federal agencies are now formally reviewing whether marijuana should be moved to Schedule III, a change would acknowledge medical value and significantly alter how cannabis businesses are taxed and regulated. A rescheduling decision would not legalize marijuana nationwide, but it could ease restrictions on research, improve access to banking services and remove a major tax burden faced by licensed operators.
While momentum has grown, federal officials have not finalized a decision, making 2026 a critical year to watch for regulatory clarity.
Photo by Anton Petrus/Getty Images
Another major issue unfolding in 2026 involves hemp-derived THC beverages, which surged in popularity as alcohol alternatives. These drinks, often sold outside licensed cannabis dispensaries, exist in a gray area created by the 2018 Farm Bill.
New federal and state proposals aim to redefine what qualifies as legal hemp, potentially restricting or eliminating intoxicating hemp products altogether. Some states are moving to regulate hemp drinks like alcohol, while others are considering outright bans.
The outcome could reshape the beverage market, impact small hemp businesses and determine whether THC drinks remain widely available or move exclusively into regulated cannabis systems.
If federal rescheduling moves forward, it is expected to unlock greater medical research funding and streamline approval for clinical trials. For decades, cannabis research has lagged due to regulatory hurdles.
Medical professionals and researchers are increasingly studying cannabis for its potential benefits in treating or alleviating symptoms related to:
Chronic and neuropathic pain
Cancer-related nausea and appetite loss
Epilepsy and seizure disorders
Post-traumatic stress disorder (PTSD)
Multiple sclerosis
Anxiety and sleep disorders
Inflammatory and autoimmune conditions
More funding could lead to standardized dosing, clearer safety guidelines and wider acceptance within mainstream medicine.
At the state level, cannabis remains a legislative priority in 2026. Several states are reviewing or carrying over bills related to legalization, medical expansion or criminal justice reform.
Among those under active consideration are Pennsylvania, North Carolina, South Carolina, Tennessee and Texas, each weighing changes ranging from expanded medical access to reduced penalties for possession. While not all proposals are expected to pass, the continued debate reflects shifting public opinion and political pressure.
Taken together, 2026 could mark a turning point for cannabis in the United States. Federal rescheduling, tighter hemp regulation, increased medical research and renewed state legislative efforts suggest a slow but steady move toward normalization — even as legal contradictions persist.
For consumers, patients and policymakers alike, the year ahead will help determine whether cannabis continues its gradual integration into American medicine, commerce and culture — or remains caught between reform and restriction.
Explore the best ways cannabis can make the new year awesome for calm, fitness, pain relief, and healthier routines.
The New Year often arrives with a familiar mix of optimism and resolve. People vow to feel better, move more, sleep deeper, and manage stress with greater intention. Increasingly, cannabis is part of the conversation—not as a counterculture indulgence, but as a wellness tool embraced by adults seeking balance, moderation, and healthier alternatives. Here are the best ways cannabis can make the new year awesome.
Stress management remains a top priority each January, and cannabis is increasingly used to support mental well-being. Certain products are favored for their ability to promote relaxation and emotional balance rather than stimulation. When used responsibly, cannabis may help quiet racing thoughts, ease physical tension, and encourage moments of calm. Many people pair cannabis with mindfulness practices such as meditation, stretching, or journaling to reinforce healthier mental habits.
Photo by rawpixel.com
One of the fastest-growing trends in cannabis is microdosing. Rather than consuming enough to feel intoxicated, users take very small amounts designed to deliver subtle benefits. Advocates say microdosing can gently elevate mood, sharpen focus, and take the edge off anxiety without interfering with work or daily responsibilities. For many professionals, it offers a way to stay engaged and productive while still enjoying cannabis’s calming properties.
Another major lifestyle change gaining momentum is the movement away from alcohol and toward cannabis. As more adults reassess their relationship with drinking, cannabis is emerging as a gentler social and personal alternative. Unlike alcohol, cannabis does not dehydrate the body or disrupt sleep in the same way, and many users report waking up clearer and more refreshed. In social settings, low-dose cannabis can help people relax and connect without the downsides often associated with heavy drinking.
For medical cannabis patients, the New Year can bring renewed hope for managing chronic conditions. Cannabis is commonly used to help address ongoing pain, inflammation, nerve discomfort, and muscle spasms. By reducing pain levels, medical cannabis may enable better sleep, increased mobility, and improved quality of life. For many, it becomes a key component of maintaining daily function and overall wellness.
Cannabis is also finding a place in fitness and active lifestyles. Some individuals use small amounts before exercise to improve focus or deepen mind-body awareness, while others turn to cannabis after workouts to support relaxation and recovery. By helping ease muscle soreness or inflammation, cannabis may make it easier for people to stay consistent with movement—an essential factor in long-term fitness success.
As attitudes continue to evolve, cannabis is increasingly viewed through a lens of intention rather than excess. Used thoughtfully, it can support calm, recovery, and balance—qualities many people prioritize at the start of a new year. For those seeking healthier habits and sustainable change, cannabis may offer a modern tool for making the year ahead not just new, but genuinely better.
Can cannabis help with anger explore science stress relief and mindful use in todays tense world.
Right now, the national mood feels tense. Everyday living costs are stubbornly high, political turmoil dominates headlines, and many people feel society has shifted toward self-interest rather than the greater good. Add constant notifications, long commutes, and financial anxiety, and it’s no surprise anger feels closer to the surface than calm. It can play out in a variety of ways – from Congressman Chris Garten posting beating up Santa (R-IN) to spiking high blood pressure. In moments like these, people look for healthy ways to decompress—and for some adults, cannabis has entered the conversation as a possible tool to help cool hot emotions.
So, can cannabis help with anger? The short answer: it can help some people feel calmer, but how and why matters.
Anger is often a secondary emotion. Beneath it sit stress, fear, exhaustion, and a sense of lost control. When prices rise faster than paychecks, when political debates feel relentless, and when empathy seems in short supply, the nervous system stays in a constant state of alert. The “always on” stress response primes the body for irritability and short tempers.
Many adults are not looking to “escape” reality—they’re looking for relief, perspective, and a way to slow their racing thoughts. This is where cannabis, used thoughtfully, may help.
Rep Garten (R-IN) posted a pic of his beating up Santa Claus
Cannabis interacts with the body’s endocannabinoid system, which plays a role in mood regulation, stress response, and emotional balance. Certain cannabinoids and terpenes are associated with relaxation and reduced stress, which can indirectly soften anger.
1. It can reduce stress, the fuel behind anger. High stress often turns small annoyances into major blowups. Many people report cannabis helps lower baseline stress, making it easier to respond rather than react.
2. It encourages mental pause and perspective. Anger thrives on speed—fast thoughts, fast judgments, fast words. Cannabis can slow the mental momentum, giving users space to reflect before reacting.
3. It may relax the body, not just the mind. Tension in the shoulders, jaw, and chest often accompanies anger. Cannabis is known for its muscle-relaxing effects, which can help break the physical feedback loop keeping anger alive.
4. It can support better sleep. Poor sleep and anger are closely linked. When people are exhausted, emotional regulation drops. For some adults, cannabis supports more restful sleep, which can translate into a calmer mood the next day.
Not all cannabis experiences are calming. High doses of THC, especially for inexperienced users, can increase anxiety or irritability. Many people seeking emotional balance gravitate toward lower-THC products or strains known for soothing terpene profiles such as myrcene or linalool.
Microdosing—using just enough to feel relaxed without feeling impaired—has become a popular approach for those looking to manage mood without losing clarity or motivation.
To be clear: cannabis doesn’t solve the root causes of anger. It won’t lower grocery prices or heal political divisions. What it can do is help some adults create a calmer internal state, making it easier to communicate, reflect, and respond thoughtfully rather than explosively.
Used responsibly, cannabis may support anger management by helping people slow down, soften their reactions, and reconnect with a sense of balance. In a time when tempers are running high nationwide, a pause—however small—can make a meaningful difference.
As Michigan’s recreational cannabis industry begins its seventh year this year, cannabis customers have more choices than ever.
More than 1,000 growers and processors are producing flower, concentrates, and other cannabis products across the state. With new cultivators, genetics, and extraction techniques, the market continues to evolve and set higher standards.
But abundance has its downsides. With so many choices, finding the right cannabis can be exhausting and expensive. Some flower and concentrates are exceptional, grown and processed by brands that care about the craft and prioritize quality. But much of the market is dominated by companies that churn out cheap, poorly grown weed.
If you’re looking for something better than the McDonald’s version of cannabis, Metro Times can help point the way. Over the past few months, I set out in search of the best flower and live rosin (a solventless concentrate known for its flavor and potency) that will be available in 2026.
Great cannabis is about more than THC percentages or flashy packaging. It’s craftsmanship and passion for the plant. It’s taking the time to hunt for the right genetics, growing for quality over yield, and properly cure the harvest.
After months of smoking, dabbing, and taking notes, these are the flower and live rosin strains that stood out from the rest. They are flavorful, visually striking, smooth, consistent, and deliver a memorable high.
Ten best flower strains:
Lantz by Hytek. Credit: Steve Neavling
Lantz by Hytek is one of the most unique strains I tried in 2025, and I couldn’t get enough of it. The Detroit-based cultivator won best tasting and best overall flower at the Zalympix last year for Lantz, a hard-hitting and flavorful hybrid cross of Ridgeline Runtz and Green Lantern. The flavor profile features cream and tart lime followed by a floral sweetness and forest pine. It’s hard to go wrong with Hytek, which grows some of the best flower in Michigan.
Honey Banana by Growing Pains. Credit: Steve Neavling
Honey Banana by Growing Pains is the most flavorful flower I’ve had in 2025, and the Paw Paw brand is continuing to grow it this year. A cross between Strawnana and Honey Boo Boo, the flower smells and tastes like banana bread stuffed with strawberries and honey and a dash of tea. While the buds are lighter and wispy, they are coated in sticky trichomes and deliver a relaxing, happy high. Not surprisingly, Honey Banana won three Zalympix awards in 2025. Can’t find Honey Banana? Growing Pains has plenty of other high-quality strains.
Mandarin Z by Information Entropy. Credit: Steve Neavling
Mandarin Z by Information Entropy is an energizing strain made by crossing Mandarin Sunset and California Black Rose. The Ann Arbor-based cultivator produces big, plump, trichome-heavy buds, and this is my favorite strain from them. It has a sweet orange flavor, with delicious notes of spice and herbs. Other great strains from Information Entropy are Project Z, Sherb Cream Pie, Motorbreath #15, Apple & Bananas, and Limon Mandarina. If you can’t make it to Information Entropy’s dispensaries in Ann Arbor or New Buffalo, Bowdega in Utica also carries their flower.
Headstash #1 by the Hive. Credit: Steve Neavling
Headstash #1 by the Hive in Hazel Park is an energizing strain with a citrus and funky aroma. A cross between Lime #1 and Headband, this strain is potent and uplifting, making it a perfect daytime choice. The Hive, a woman-owned dispensary and small-batch cultivator, brings the heat with all of its flower, making this a tough choice. Other great hybrid and sativa-leaning strains by the Hive are Superboof, Candy Sherb, Dolce de Fresa, Permanent Marker, and Party Runtz.
Ice Cream Mints by the Hive. Credit: Steve Neavling
Ice Cream Mintz is another incredible new strain by the Hive. Unlike Headstash #1, this strain is calming and perfect for a late evening at home. A combination of Ice Cream Cake and Kush Mints, this strain tastes like sweet, creamy vanilla and crisp mint. Other good indica-dominant strains from the Hive are Rainbow Beltz, Motorbreath #15, Ice Creature, Pink Zoap, Hash Bee OG, and Sherb Cream Pie.
Sunset Animal by Mi Loud. Credit: Steve Neavling
Sunset Animal is one of Mi Loud’s newest strains, and the Jackson brand has proven it’s still one of the most premium cultivators in Michigan. Known for its funky, fuel-soaked strains, Mi Loud is beginning to mix it up with sweeter and fruity flavors. Sunset Animal is a sweet, creamy strain that smells like tropical fruit, with subtle notes of nuts and floral spice. A cross between Sunset Sherbet and Animal Cookies, this strain is euphoric, uplifting, and relaxing. One of my favorite cultivators in Michigan, you can’t go wrong with any of Mi Loud’s strains.
Speaker Knockerz by Mi Loud. Credit: Steve Neavling
Another standout by Mi Loud, Speaker Knockerz is a bold, flavorful strain with a sweet, fruity aroma with notes of earth, herbs, and citrus. The buds are covered in thick trichomes and produce a well-balanced high. Speaker Knockerz is a cross between Runtz and Animal Mintz. Other top-tier Mi Loud strains are OGKB2.1, Dunestar, Jar Jar Stinks #21, Guava Juice, Garlic Cocktail, and Pierene.
Maize & Blue by Premier Cannabis Farms. Credit: Steve Neavling
Maize & Blue Belts by Premier Cannabis Farms is one of the most relaxing and flavorful strains on the market. A fruity cross of Oregon Blueberry and Rainbow Belts, this strain is a tribute to the University of Michigan’s football team. The flavor profile is gassy and doughy with ripe berries. It’s a perfect choice for chilling out and letting go of stress.
Cherry Zest #4 by 710 Labs.
Cherry Zest by 710 Labs may be expensive — up to $50 for an eighth — but it’s delicious and produces a tranquil high. A cross of Z and Animal West, Cherry Zest is a refreshing mix of fresh cherries and ginger ale, with a sweetness that lingers in the mouth. The high is calm and body-heavy, making it perfect for listening to music or winding down at the end of the night. It’s easily one of the most flavorful strains I’ve tried. For a closer look at other 710 Labs flower, check out my column from November.
Tazmanian Tantrum by Michigrown.
Tazmanian Tantrum by Michigrown is a unique, relaxing, and potent strain with a menthol, earthy, and spicy aroma. A cross between Dizco Fever and Diablo OG x TK Stardawg, this strain produces large, sticky buds sold in jars and prerolls. The Muskegon cultivator has an enormous library of strains, so if you can’t find Tazmanian Tantrum, there are still plenty of choices.
The 10 best live rosin strains:
HY-Z by Hytek. Credit: Steve Neavling
HY-Z by Hytek is my favorite z-terp (think sweet candy) strain on the market. A cross between Zkittlez and Gelato 41, the bold flavor of tropical fruit and candy sticks to the tongue and throat long after the exhale. The effects are balanced and uplifting, making it a good choice for anytime of day. With a smooth, creamy texture and a pearl-like color, this is the sexiest rosin I’ve come across in Michigan. Hytek raised the bar for rosin after snagging a real pro to make the solventless extract in late 2025. This is going to be an exciting year for Hytek.
Hardcore OG by Hytek. Credit: Steve Neavling
Hardcore OG is another gem by Hytek. With an unknown OG lineage, this strain has the classic OG flavor, but with a sweet herbal taste. Great for relaxing, the strain has sedate and euphoric effects that are ideal for winding down. Like HY-Z, the rosin is smooth and creamy with a pearl color. Other good Hytek rosin strains are Strawguava, Lantz, Los Muertos, and Dolato.
Orange Yuzu by Exotic Matter. Credit: Steve Neavling
Orange Yuzu by Exotic Matter is my go-to daytime strain. A cross of Superboof and Gelonade, this one boasts a bold citrus aroma with some funk on the backend. The rosin has a smooth, creamy texture that is incredibly easy to work with. The high is energizing and euphoric, making it a great choice for any time you need a lift up. Another bonus is that Exotic Matter is nearly half the price of many top rosin makers, despite its high quality. Other Exotic Matter recommendations are Papaya (one of the best in the state), Purple Drank, Pineapple Whips, Banana Candy, Tropical Strawberry, Tropical Zlushee, and Galactic Warheads.
D-Lish by Eastside Alchemy. Credit: Steve Neavling
D-Lish is one of the newest strains by Eastside Alchemy, a small, tight-knit operation based in Lansing that focuses solely on live rosin. A combination of Zkittlez and Sweet Retreat, D-Lish lives up to its name with a flavor profile of grapes, sweet candy, and tropical fruit. What really makes this strain special is its effects — it’s soothing, euphoric, and heightens the senses. Other top-tier Eastside Alchemy strains on the shelves this year are Rainbow Guava, the Hive, Swamp Water Fumez, Papaya Juice, Maple Bacon, Z-Hive, Too Much Grape #5, and Rose Fuzz #11.
Pomelo Punch by Eastside Alchemy. Credit: Steve Neavling
Pomelo Punch #5 by Eastside Alchemy is a delicious and potent hybrid made by crossing Orange Mints and Papaya. The rosin smells tangy and citrusy and tastes like tart grapefruit on the frontend and a sweet fruit punch on the backend. The dynamic, complementary flavors are what I love most about rosin, and this strain nails it.
Rainbow Push Pop by Local Grove. Credit: Steve Neavling
Rainbow Push Pop by Local Grove is truly a special treat. An indica-leaning cross of Orange Mintz and TMZ, this strain smells like a lemon lime push pop with orange and notes of sherbet that linger in the mouth. The rosin is moist and soft with a light-yellow color. Local Grove has been releasing some of the best rosin in the state. Other great strains are Gogurtz, Brain Stew, Garlic Drip, Spritzer, Swamp Water Fumez, and Spritzer.
Tallymon by Local Grove. Credit: Steve Neavling
Tallymon is another flavor bomb by Local Grove, which has become one of the best rosin producers in Michigan. A cross between Banana OG x Dosidos and Papaya, Tallymon is an evenly balanced hybrid that produces one of my favorite uplifting, euphoric highs. The flavor is delicious, with a mouthwatering taste of tropical fruit and creamy banana, and the badder is moist and soft like warm butter.
Banana Boat by Wojo. Credit: Steve Neavling
Banana Boat by Wojo recently hit the shelves, and it’s impressive. A cross of Dubble Motorboat/ICC and Honey Banana, this energizing strain tastes like a banana soaked in fuel. The rosin is creamy and light yellow. One of the most reputable producers of rosin, Wojo has an impressive library of strains, and many of them are back in 2026. My favorites on the shelves now are Honey Combz, Malibu Marsha, Berry Blackout, Strawberry Candy, DOW, Oishii, Sundae Driver, and Tangerine Limousine.
Rambutan by 710 Labs. Credit: Steve Neavling
Rambutan #11 by 710 Labs is an upbeat strain that bursts with flavor. A combination of Papaya and Guavaz #74, this strain is sweet and fruity with a funky backend. The first-pressPersy rosin is glassy and translucent, but it’s not easy to work with if you’re new to rosin. A longtime leader in top-tier rosin, 710 Labs has an impressive array of strains. My favorites available this year are Mango Banana #9, Sundae Driver, Cereal Star #5, Strawberry Guava #9, Gak Smoovie #5, and Lemon Heads #4.
Triple Burger by Ice Kream Hash Co. Credit: Steve Neavling
Triple Burger by Ice Kream Hash Co. is a sedate, pungent strain that brings on the funk. A cross between GMO and Double Burger, this strain has an aroma of garlic, butter, and diesel, in the best possible way. Like many funky strains, this one is tranquil, so it’s best suited for the evening. I also found this is good for pain relief. The rosin has a golden tone and a wet shine.
The best way to find these strains near you is to use High Spy, a nifty site that keeps track of products available at each dispensary.
Don’t let this list limit you. The recreational market has a lot of incredible flower and live rosin, and the easiest way to find it is to search for reputable cultivators. Some of the top cultivators for flower are Exotic Matter, Freshy Fine, Ghostbudsters, Growing Pains, the Hive, Hytek, Information Entropy, Mi Loud, Michigrown, Peninsula Gardens, Premier Cannabis Farms, Ripe Herb, and Tip Top Crop. All of them have high-quality strains that are usually fresh, flavorful, and potent.
For live rosin, my favorites are 710 Labs, Eastside Alchemy, Exotic Matter, Growing Pains, Hytek, Ice Kream Hash Co., Local Grove, Mi Loud, Superior Solventless, and Wojo. And if you like prerolls, check out our list of the best joints in the Michigan market.
Can you mix alcohol and marijuana on NYE learn how to balance buzz vibes and next morning happiness
New Year’s Eve is built for indulgence. Champagne and wine flows, cocktails shimmer, and for many adults, cannabis has become part of the celebration. But when the clock is ticking toward midnight, a common question bubbles up right alongside the champagne: can you mix alcohol and marijuana on NYE — and if so, how do you do it smartly?
The short answer: yes, you can mix them — but how you do it matters more than ever.
Alcohol is a depressant which lowers inhibitions and speeds up decision-making. Cannabis, depending on the strain and dose, can either mellow you out or make sensations feel more intense. When combined, the effects don’t just stack — they amplify. That amplification can be delightful in small amounts… or uncomfortable if you overdo it.
This is why seasoned celebrators add an additional golden rule: microdose first, sip second. This goes with the old saying of “beer before liquor, never been sicker; liquor before beer, you’re in the clear”.
If you plan to combine cannabis and alcohol on New Year’s Eve, microdosing is your best friend. Instead of a full edible or a heavy pour, think less than you normally would — of both.
Edibles: Start with 2–2.5 mg of THC, not 10 mg.
Flower or vape: One or two small puffs, then wait.
Beverages: Choose low-ABV cocktails, wine spritzers, or beer instead of hard liquor.
Give yourself at least 30–45 minutes before adding alcohol. Cannabis can increase alcohol absorption, meaning drinks may hit harder and faster than expected.
There’s an old saying among experienced users: “Grass before glass, you’re on your… class.” Jokes aside, consuming cannabis before alcohol often leads to a smoother, more controlled experience. Doing it the other way around can increase dizziness and nausea — especially once edibles kick in.
If you’ve already had a few drinks, it’s wise to skip cannabis entirely or keep it extremely light.
One of the biggest myths is annabis prevents hangovers. It doesn’t — but it can help you drink less, which absolutely does.
Smart strategies include:
Alternate every alcoholic drink with water or sparkling water
Eat before and during the evening (protein and healthy fats help)
Avoid sugary mixers late at night
Stop drinking at least an hour before midnight and switch to water or cannabis only
Many people find cannabis encourages slower sipping, fewer drinks, and an earlier, happier bedtime — all wins for January 1st.
New Year’s Eve is about celebration, not excess. A low-dose edible paired with a glass of champagne, or a cannabis beverage alongside a light cocktail, can elevate the night without derailing it.
The goal isn’t to get as altered as possible — it’s to feel good, stay social, remember the countdown, and wake up ready for the year ahead.
If you choose to mix cannabis and alcohol this New Year’s Eve, do it intentionally. Start low, go slow, hydrate often, and listen to your body. When done thoughtfully, cannabis and alcohol can coexist — creating a relaxed, joyful, and surprisingly hangover-light way to ring in the New Year.
The latest on medical cannabis and ALS explores symptoms, research, patient relief options, and emerging clinical insights
It has been in the news with actor Eric Dane struggling with the ALS. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, remains one of the most challenging neurological disorders confronting patients and clinicians today. Characterized by the progressive degeneration of motor neurons—the nerve cells that control voluntary muscles—ALS leads to muscle weakness, loss of mobility, difficulty speaking and swallowing, and ultimately respiratory failure. There is currently no cure for ALS, and most individuals diagnosed with the condition live only three to five years after symptom onset. Treatments focus on slowing progression and managing symptoms to improve quality of life. But what is the latest on medical cannabis and ALS.
Patients with ALS may first notice subtle symptoms such as muscle twitching, weakness in a limb, or slurred speech, which gradually evolve into more severe impairments affecting daily living. As the disease progresses, individuals often struggle with activities like walking, speaking, eating, and breathing. While cognitive function is usually preserved, some people experience changes in emotional expression and mood. There is a strong emphasis in clinical care on coordinated support—spanning physical therapy, respiratory assistance, nutritional counseling, and psychosocial support—to address complex patient needs.
Amid ongoing research into traditional pharmaceuticals and genetic therapies, interest has grown in the potential role of medical cannabis as a complementary approach for symptom management in ALS. Cannabinoids—the active compounds in cannabis such as THC (tetrahydrocannabinol) and CBD (cannabidiol)—interact with the body’s endocannabinoid system, which is involved in regulating pain, muscle tone, appetite, and mood. Preclinical studies in animal models suggest cannabinoids might exert antioxidative, anti-inflammatory, and neuroprotective effects could slow the degeneration of motor neurons, though more rigorous clinical trials in humans are needed.
In patient surveys and early clinical observations, people with ALS have reported medical cannabis helps relieve several symptoms commonly associated with the disease. These include pain, poor appetite, anxiety, muscle cramps, spasticity, and drooling. Some users also report improvements in sleep quality and overall well-being. However, it’s important to note the definitive evidence of long-term benefits or effects on disease progression in humans is still limited, and outcomes can vary widely between individuals. A recent retrospective study found short-term symptom relief for pain and anxiety with medical marijuana use but also observed a correlation with faster functional decline, underscoring the complexity of interpreting these findings and the need for controlled clinical research.
Ongoing trials—such as placebo-controlled studies evaluating cannabis-based extracts for slowing disease progression—aim to clarify whether cannabinoids have a measurable impact on ALS beyond symptom relief. As researchers continue to explore both conventional and alternative therapies, patients and clinicians alike emphasize individualized care plans weigh potential benefits, side effects, and legal considerations related to medical cannabis. For authoritative research news, advances in clinical trials, and emerging treatment strategies beyond cannabis, consider the ALS Association and academic neurology publications as additional resources.
Medical cannabis is not a cure for ALS, but for some patients it may offer meaningful relief of specific symptoms when used under medical supervision. The landscape of ALS treatment is evolving, and continued research will help clarify where cannabis may fit within broader therapeutic strategies for this devastating disease.
What does the public think about rescheduling cannabis in a post-prohibition era driven by data, not stigma.
What does the public think about rescheduling cannabis? Long before federal officials formally moved to reschedule cannabis, they had already made up their mind. According to a widely cited poll from Pew Research Center, 88% of Americans supported legal cannabis in some form—either for medical use, adult use, or both—prior to the rescheduling announcement. The overwhelming consensus set the stage for what many see as a long-overdue policy shift catching up with reality.
Post-rescheduling polling shows public opinion has only grown more confident, particularly around cannabis’s medical potential. A December 2025 survey from YouGov found more than three-quarters of U.S. adults believe cannabis has legitimate medical uses, while just a small minority disagreed. Notably, the poll also showed broad approval for rescheduling specifically because it allows expanded medical research—an issue which resonates across party lines.
Another YouGov medical-focused poll reinforces the point. Large majorities said cannabis should be studied and made available as a treatment option, especially where conventional therapies fall short. This is not abstract support; it reflects lived experience. Veterans coping with PTSD consistently report medical cannabis can help manage anxiety, nightmares, and sleep disruption when traditional medications fail or cause harsh side effects. For many, rescheduling represents validation rather than experimentation.
Patients with cancer, IBS, and chronic pain echo similar sentiments. Poll respondents frequently cite cannabis’s ability to ease nausea from chemotherapy, stimulate appetite, reduce inflammation, and improve sleep quality. Sleep, in particular, stands out as a near-universal concern—one where many Americans say cannabis has helped them fall asleep faster and stay asleep longer.
The impact extends beyond people. Everyday pet owners increasingly report using CBD products to calm anxious dogs during fireworks, ease joint pain in aging pets, and improve overall quality of life. While veterinarians urge careful dosing and further study, public acceptance of pet-focused CBD mirrors the broader shift toward viewing cannabis as a wellness tool rather than a cultural wedge issue.
Taken together, these polls paint a clear picture. Americans are not debating whether cannabis belongs in modern medicine—they are asking how best to regulate, research, and responsibly use it. Rescheduling did not change public opinion; it aligned federal policy with a public already convinced cannabis can help real people, and even their pets, live better lives.
Feds reveal medical cannabis is very popular with the disabled, according to a new federal study examining pain relief, access and policy implications.
In a move displaying the practical use of marijuana, the feds reveal medical cannabis is very popular with the disabled for a sound reason. A newly released federal study finds Americans living with disabilities are increasingly using cannabis to manage pain, stress and other chronic symptoms, underscoring a growing gap between patient behavior and federal drug policy.
The research, published in the Disability and Health Journal and funded by the National Institute on Disability, Independent Living, and Rehabilitation Research, draws on data from nearly 2,000 adults who self-identify as having a disability. About 22 percent of respondents reported current cannabis use, a rate notably higher than estimates for the general adult population.
Pain relief was the most frequently cited reason for use. More than 70 percent of participants said they use cannabis to manage pain, while roughly 60 percent reported using it to relax or reduce tension. Others cited relief from migraines, nausea, muscle spasms, sleep disturbances, seizures and mental health symptoms. Participants represented a wide range of disability types, including mobility, cognitive, vision, hearing, self-care and independent living limitations.
Researchers note the data is self-reported and not nationally representative, with respondents skewing toward white, female and college-educated individuals. Still, the authors concluded cannabis use is prevalent across disability categories and warrants greater attention from public-health officials and policymakers.
The findings arrive as the administration weighs whether to follow through on plans to reschedule cannabis under the Controlled Substances Act. Marijuana is currently classified as a Schedule I substance, a category reserved for drugs with no accepted medical use, despite growing evidence and widespread patient use. Moving cannabis to Schedule III would formally acknowledge its medical value and reduce barriers to research.
For patients with disabilities, rescheduling is not an abstract policy issue. Federal classification affects everything from clinical research and physician guidance to affordability and access. Because cannabis remains federally restricted, doctors often lack clear guidelines, large-scale clinical trials remain limited, and insurance coverage is nonexistent. Patients are left navigating a patchwork of state rules while managing complex health needs.
Advocates say the study highlights how policy has lagged behind reality. Millions of Americans with chronic conditions are already using cannabis as part of their care, often after conventional treatments failed or caused severe side effects. Many report turning to cannabis to reduce reliance on opioids, muscle relaxants and sleep medications, which can carry significant risks with long-term use.
Public-health experts warn continued delay has consequences. Without expanded research and standardized medical guidance, patients rely on trial and error rather than evidence-based care. For people with disabilities, who frequently manage multiple conditions at once, the uncertainty can be particularly harmful.
Rescheduling would not legalize cannabis nationwide, but it would ease research restrictions, encourage clinical studies focused on disability-related conditions, and provide clearer guardrails for physicians and patients alike. Supporters argue it would move cannabis use out of the shadows and into a more accountable medical framework.
As federal officials debate next steps, the study adds urgency to the discussion. For people living with daily pain and functional limitations, cannabis is not about recreation. It is about relief. The question now is whether federal policy will catch up with the patients already depending on it.
Any amount of regular marijuana use has a negative impact on teens’ academic performance, new research suggests.
Using cannabis products just once a month was associated with worse grades and more emotional turmoil in teenagers, according to a study published Tuesday in the journal Pediatrics.
“A few ‘harmless’ joints can snowball into real academic consequences,” said Dr. Ryan Sultan, the study’s lead author. “Teens using it regularly often struggle to focus, miss school, and may lose interest in their future plans.”
The findings come at a time when overall drug use has been at historically low levels among teens. Marijuana is the exception — with about 1 in 5 high schoolers reporting using cannabis, according to the National Center for Drug Abuse Statistics.
At the same time, cannabis products have become much more potent in recent decades. Levels of THC, or Delta-9-tetrahydrocannabinol — which causes the mood-altering effects of the drug — rose from about 4% in 1995 to more than 16% in 2022. Most cannabis products available now have potencies over 20%, according to a recent report.
For the new study, researchers analyzed data from more than 160,000 eighth-, 10th- and 12th-graders from national surveys conducted between 2018 and 2022. More than a quarter of the group said they used cannabis products, with 18% reporting near-daily use, 14% weekly use and 18% monthly use.
Monthly users were twice as likely to do poorly in school and get into fights compared with students who did not use. Students who used cannabis products were also at higher risk for depression and anxiety.
Students who used weed nearly every day were four times more likely to have low grades and to be disengaged from school, the study found.
“A teenager’s brain is still developing the circuits for learning, self-control, and emotional regulation,” saidDr. Tim Becker, one of the study’s co-authors and a child and adolescent psychiatrist at NewYork-Presbyterian Westchester Behavioral Health. “Using cannabis, even casually, during these critical growth periods interferes with those processes and can derail normal development.”
Has cannabis claimed its first alcohol victim? Jim Beam’s production pause may reveal shifting drinking trends.
Cannabis has surged in popularity across the United States in recent years, cutting across age groups from older medicinal users to younger adults who increasingly embrace it for recreational and wellness purposes. As cultural attitudes shift and legal access expands — now with major moves at the federal level to reschedule cannabis — traditional alcohol consumption patterns are visibly changing too. Emerging data show younger generations, especially Generation Z, are drinking far less than their predecessors, opting instead for alternatives like cannabis or choosing moderation for health and lifestyle reasons. Drinking rates among adults under 35 have steadily declined over the past two decades, underscoring a generational shift away from habitual alcohol use. And the question is has cannabis claimed its first alcohol victim?
At the federal level, the United States is on the brink of historic change in how it views and regulates cannabis. The current administration has taken formal steps toward rescheduling marijuana, acknowledging its accepted medical uses and easing long-standing federal restrictions. While rescheduling does not equate to full legalization, it would reduce regulatory barriers, expand medical research opportunities, and significantly alter the financial and operational landscape for the legal cannabis industry. These moves reflect a broader cultural shift in which cannabis is increasingly normalized, while alcohol faces mounting competition for consumer attention and dollars.
Photo by 2H Media via Unsplash
Those changing preferences are now rippling through the alcohol industry. A striking example emerged with the announcement Jim Beam will pause production at its flagship distillery in Clermont, Kentucky, beginning in 2026. The move was made by parent company Suntory Global Spirits as part of a strategic adjustment to address slowing demand and an oversupply of aging bourbon barrels. While bottling, warehousing, and visitor operations will continue, a full production pause at one of the most iconic bourbon sites in the world is an unusually strong signal the industry is recalibrating.
Multiple pressures are converging at once. Kentucky warehouses are holding record levels of bourbon, domestic spirits consumption has softened, and international sales have been hit hard by tariffs which have significantly damaged export markets. Canada, historically one of the most important destinations for American whiskey, has been particularly affected, with higher costs and retaliatory trade measures sharply reducing demand. Together, these forces have made it harder for even legacy brands to justify uninterrupted production.
To fully grasp the significance, it helps to revisit the history of Jim Beam itself. Founded in 1795 when Jacob Beam sold his first barrels of whiskey in Kentucky, the brand is one of the oldest continuously produced bourbons in the world. Jim Beam survived Prohibition, rebuilt under James Beauregard “Jim” Beam in the 1930s, and went on to become a global symbol of American whiskey.
At the height of its popularity in the late 20th and early 21st centuries, Jim Beam was ubiquitous — a staple on back bars, a fixture at family gatherings, and a cultural shorthand for bourbon itself. While the brand remains strong, the current pause suggests a changing landscape where tradition alone is no longer enough. Whether cannabis has claimed its first true alcohol casualty remains up for debate, but the shift in American consumption habits is no longer theoretical — it is playing out in real time, barrel by barrel.
The Feds support shipbuilding but compared to marijuana which of these two industries contribute more to the economy.
In recent months, the current presidential administration has made shipbuilding a visible national priority, citing economic security, defense readiness, and the need to rebuild American industrial capacity. Federal speeches, policy directives, and funding discussions have elevated shipbuilding as a symbol of manufacturing revival. At the same time, the cannabis industry continues to receive cautious, uneven federal attention. While it has moved forward on rescheduling, Mmarijuana remains illegal at the federal level. Reform legislation advances slowly despite strong public support. The contrast between robust federal backing for shipbuilding and the tepid, uncertain approach toward cannabis shapes a broader debate over which of these two industries contribute more to the economy?
Measured purely by scale, the two industries look very different. U.S. shipbuilding today is a relatively small and highly specialized sector. The country currently produces roughly three large commercial ships per year, with shipyards concentrated in a handful of coastal states. According to commonly cited labor estimates, including those referenced by industry analysts and public employment data, the average shipbuilding salary is about $59,000 annually. While some skilled welders, engineers, and managers earn more, an average reflecting a workforce closer to the national median wage than many assume.
Photo by smodj/Getty Images
The cannabis industry, by contrast, operates at far greater scale. Legal marijuana supports more than 400,000 jobs nationwide across cultivation, manufacturing, retail, compliance, logistics, and technology. Industry revenues exceed $30 billion annually, with legal sales spread across more than half the states. Average wages vary widely, but many full-time cannabis workers earn salaries comparable to shipbuilding employees, particularly in regulated states with established markets.
One of the most important economic differences is time. Even with full federal support, shipbuilding cannot expand quickly. Building new shipyards, modernizing facilities, training skilled labor, and securing supply chains takes years, often decades. Workforce pipelines require long-term investment in apprenticeships and technical education, and new production capacity cannot be switched on quickly. Economic benefits from expanded shipbuilding, while real, will be gradual and regionally concentrated.
Cannabis growth follows a very different pattern. Because the industry is already operating in dozens of states, economic expansion can happen rapidly when regulations change. New licenses, retail stores, and cultivation sites can open in months, not years. Tax revenue flows immediately once sales begin, and employment grows alongside local demand. This speed matters at a time when states are looking for near-term economic relief and job creation.
Another key distinction is ownership. Shipbuilding is dominated by large contractors and defense-linked firms. Cannabis, on the other hand, has supported thousands of small and mid-sized businesses. Many dispensaries, farms, manufacturers, and ancillary companies are locally owned, creating opportunities for entrepreneurs and keeping profits within communities. These mom-and-pop operations contribute to neighborhood employment, commercial real estate occupancy, and local tax bases in ways large industrial projects often do not.
From a tax perspective, cannabis already delivers significant returns to state governments through excise taxes, sales taxes, and licensing fees, funding schools, infrastructure, and public health programs. Shipbuilding generates tax revenue primarily through payroll and corporate activity, but its overall footprint is smaller due to limited production volume.
Shipbuilding remains strategically important and worthy of investment, particularly for national security and industrial resilience. But economically, cannabis already touches more workers, more states, and more local economies, despite operating under federal restrictions. The comparison suggests while shipbuilding represents a long-term industrial project, cannabis is a functioning, revenue-generating sector whose economic contributions are already being felt across much of the country.
A Hazel Park dispensary is closing its doors on Christmas eve, becoming at least the 14th cannabis business to shutter in the city as the cutthroat recreational marijuana industry continues to struggle with too many stores and plummeting prices.
Clarity is just the latest victim of an industry that has more cannabis than it can sell. Prices have plummeted, and sales continue to decline this year. Profit margins are razor thin, and many businesses have closed or are on the cusp of calling it quits.
Although dozens of dispensaries, grow operations, and processors have closed in Michigan this year, state lawmakers and Gov. Gretchen Whitmer approved a new 24% wholesale tax on marijuana that industry insiders say will suffocate the industry and force the closure of more businesses. That’s on top of a 10% excise tax and a 6% sales tax.
“Layer that on top of price compression, oversupply, heavy administrative overhead, and an unpredictable enforcement climate, and the outcome is clear: even the largest, most capable operators cannot responsibly justify continued operations under this trajectory,” Trucenta CEO Zoran Bogdanovic tells Metro Times.
In addition, Bogdanovic says the state’s Cannabis Regulatory Agency (CRA) is making it difficult for businesses by imposing massive fines for small mistakes. In November, the CRA accused Trucenta of committing several violations, including improperly transporting cannabis products, misusing the statewide monitoring system, failing to maintain complete surveillance footage, and attempting to mislead inspectors by switching tags on different marijuana products. The agency’s inspection on April 11 revealed that Trucenta employees switched tags on distillate to deceive inspectors, according to the CRA’s formal complaints.
In response, Bogdanovic stresses that the company tried to comply with regulations and collaborate with the agency. He says Trucenta has been “diligently providing all requested documentation, including video footage,” and engaging with the CRA’s inquiries. However, Bogdanovic says the company has encountered delays in the CRA’s processing of its submissions.
According to Bogdanovic, Trucenta filed five formal complaints against the CRA earlier this year over concerns about what he describes as “disruptive business practices” that were not addressed before the CRA’s recent complaints.
“The regulatory and economic landscape in Michigan has reached a point where the operational risk, financial strain, and enforcement volatility no longer align with responsible, sustainable business,” Bogdanovic tells Metro Times. “This isn’t about any single event or disagreement. This is structural.”
He adds, “Over the last several years, the Cannabis Regulatory Agency has intensified its enforcement posture to a level that has created a climate of constant operational uncertainty. Formal complaints, disciplinary actions, and protracted investigations have increased across the entire state.”
Bogdanovic points out that Trucenta is far from alone. For example, TerrAscend Corp., a multistate, publicly traded cannabis company, announced this summer that it’s closing all 20 of its dispensaries and four cultivation and processing sites in the state. The company also laid off about 250 employees at its dispensaries under the Gage, Pinnacle Emporium, and Cookies brands across Michigan, with locations in Detroit, Ferndale, Lansing, Kalamazoo, Traverse City, Grand Rapids, Battle Creek, and other cities. The company is also closing its cultivation and processing facilities in Bay City, Harrison Township, and Warren.
PharmaCann shut down its massive LivWell facility in Warren in December 2024, and Curaleaf ended its Michigan operations last year. Countless small cannabis businesses have also shuttered.
In Hazel Park alone, at least one other dispensary, four grow operations, six processors, two secure transporters, and a consumption lounge have gone out of business.
Nine dispensaries still operate in Hazel Park.
Cannabis businesses in the city were also hit with at least six break-ins between January 2024 and March 2025. In August, several armed suspects were arrested after breaking into the HP Lab Group processing center on John R around 1:33 a.m Police said a security guard was disarmed, kidnapped, and bound with duct tape, and the suspects drove a U-Haul through the building.
In October, Democrats who control the state Senate introduced a set of bills on Oct. 2 that would limit each municipality to one dispensary for every 10,000 residents. If approved, the legislation would prevent the state Cannabis Regulatory Agency (CRA) from approving new dispensary licenses in municipalities that already exceed the limit. Municipalities with fewer than 10,000 residents would be limited to one retail license.
The bill wouldn’t force existing dispensaries to close, but once one shuts down, it couldn’t be replaced until the municipality falls below the cap.
If the bills pass, Hazel Park would be limited to one dispensary.
Bogdanovic says his company isn’t giving up.
“Trucenta will always stand for responsible operations, transparency, and forward-thinking leadership,” he says. “As we navigate this next chapter, our decisions will reflect one principle: doing what is right, sustainable, and aligned with the long-term health of the organization, employees, and the customers we served.”
The days of settling for your friend’s poorly rolled joints are over.
Michigan’s recreational cannabis market is teeming with prerolls, from classic one-gram joints to infused versions with glass tips. Prices range from a few bucks to $50 for a rosin-infused “doink.”
Prerolls are convenient, perfect for sharing, and an affordable way to try new strains and cultivators. Some are ideal for a night out, while others are better for a more laid-back evening.
They vary wildly in size, style, and quality. On the low end, Dragonfly churns out $1 joints stuffed with low-quality shake. The most common prerolls are one gram, have a cardboard tip, and generally range from $3 to $10. Handrolled two-gram joints, often called cannons, are a step up and usually have a wood or glass tip. Then there are prerolls infused with concentrates like live rosin or bubble hash, and they generally range from $12 to $50.
Even the names vary. There are doinks, donuts, doobies, cones, snowcones, shorties, cannons, and hash holes. Like most things, better quality usually means a higher price, though there are impressive exceptions, and I’ll share those below. The most popular prerolls are like fast food fries. They’re cheap and get the job done, but there are way better options than the corporate giants flooding dispensary shelves with mediocre products.
Many growers stuff their prerolls with dry trim and shake, while the best rely on sticky, ground-up flower.
With thousands of prerolls on the market, finding the right ones for the right moment can get frustrating and expensive. I learned firsthand. Obsessed with finding the best prerolls among a mountain of mediocre options, I smoked more than 250 different prerolls from roughly 65 cultivators this year, which came out to a little less than one a day.
But finding the right prerolls is only half the battle. Many dispensaries hang on to unsold prerolls for more than a year, so it’s important to ask your budtender for the harvest date. Anything older than four months will start to deteriorate and get dry, especially because most prerolls come in a plastic container.
Without further ado, these are my favorite prerolls in 2025.
Classic one-gram joints with cardboard tips:
Lantz by Hytek: It’s no surprise Detroit-based Hytek spun up one of the best one-gram prerolls this year after dropping Lantz, a unique and flavorful strain that was crowned best overall flower in the Zalympix, the most reputable cannabis competition in Michigan. The joint was fresh and smooth, with a creamy, tart lime aroma. The price ranges from $5 to $10, depending on where you get it. Tip: The Refinery in Detroit sells Hytek prerolls for $5. This is an evenly balanced hybrid, so it’s good for relaxing or going out. Credit: Steve NeavlingRainbow Beltz by the Hive: This independent, woman-owned dispensary in Hazel Park grows some of the best flower in Michigan, and the Hive only uses sticky, pungent buds for its prerolls. It was difficult to pick a favorite because their entire lineup dialed in, but Rainbow Beltz stood out for its candy-like flavor and soothing effects. This is ideal for a cozy night in. The Hive’s one-gram prerolls cost just $6 at its dispensary. Credit: Steve NeavlingMoon Melon by Pro Gro: This preroll has a sweet melon flavor, produces a euphoric high, and delivers a smooth pull. Pro Gro offers plenty of strains, but this was the standout. Moon Melon is an evenly balanced hybrid with effects that are both euphoric and soothing. It’s perfect for anything that doesn’t require much energy. The preroll goes for $6 to $10. Credit: Steve NeavlingLime Headz by Peninsula Gardens: With a sour lime and candy fruit flavor, Lime Headz has a refreshing taste and is one of the most energizing strains on my list. It’s a go-to for daytime smokers or a night out. The prerolls come in glass containers and sell for $8 to $10. Credit: Steve NeavlingBolo Runtz by Growing Pains: Bolo Runtz is all about the flavor, with a candy, citrus, and creamy profile. The joint was smooth and fresh and delivered a potent high. This indica-leaning hybrid is ideal when your only plans are relaxing, whether it’s at home, the movies, or a brewery. The prerolls range from $5 to $8. Credit: Steve NeavlingBubblegum Sherb by Hytek: Another of my favorites from Hytek is Bubblegun Sherb, one of the tastiest prerolls I’ve had this year. The flavor is a sweet, fruity bubblegum with notes of cream and citrus. An indica-dominant hybrid, this preroll is best enjoyed in the evening for a soothing, relaxing time. Credit: Steve NeavlingGG4 by Freshy Fine: No one in Michigan grows this old-school strain better than Freshy Fine, and their prerolls reflect that. If you’re looking for a hard-hitting joint that will leave you sedate and fully relaxed, this is the choice. The flavor is a combination of earthy and sour, with notes of diesel and pine. These sell for $6 to $10. Credit: Steve Neavling
Specialty prerolls:
Z Pie by 710 Labs: This Colorado-born company is known for its live rosin, but it also offers pungent flower. Z Pie boasts a candy-sweet, dessert-like flavor with notes of grape pie. Instead of relying on the typical cardboard filter for its one-gram “doinks,” 710 Labs uses a gluten-free rotini noodle for a tip, which helps with airflow. The effects are evenly balanced and uplifting, making it a good option for a concert or hanging out with friends. Doinks sell for about $15. Credit: Steve NeavlingMandarin Skittlez by Tip Top Crop: This hand-rolled, 1.5-gram cannon comes with a wood tip that helps bring out the tangy citrus and sweet candy-like flavor. Prepare to share because this is a large, potent joint. The effects are energizing and mood-boosting, so it works well for daytime chores, social plans, or anything that requires a bit of motivation. They’re priced at $15 to $20. Credit: Steve NeavlingApples & Bananas by Information Entropy: A two-gram cannon with a wood tip, this fatty will impress just about any stoner. The draws are incredibly smooth, making the flavor of funk, fruit, and spice more pronounced. Apples & Bananas is an evenly balanced hybrid, so it’s a versatile choice for just about any occasion. These go for $20. Credit: Steve NeavlingSlurmz by Voyage Bloom: One of the most flavorful strains to hit Michigan’s recreational market, this two-gram preroll with a glass tip packs a bold aroma of grape and crisp apples, complemented by the tangy punch of a classic energy drink. Not surprisingly, Slurmz cleaned up in the 2024 Zalymix competition in Michigan, winning for best overall flower, best terps, and best tasting. The effects are euphoric and uplifting, so take this with you on your next night out, and you’ll be the envy of your stoner friends. These sell for $20 to $26. Credit: Steve NeavlingGiraffe Puzzy by Doja: One of the most oddly named strains in Michigan, Giraffe Puzzy gives off a strong fruity, candy, and floral smell, with notes of diesel. The one-gram prerolls are short and chubby with a wood tip. The effects are evenly balanced, making it well-suited for just about any activity that doesn’t require too much exertion. At $20 each, these chubbers may be the most expensive one-gram joints in Michigan. Credit: Steve NeavlingHoney Holes by Wojo: Dubbed Honey Holes by Wojo, these beasts come with a glass tip and are stuffed with 1.5 grams of flower and 0.5 grams of rosin. Wojo makes a variety of these, and my favorite so far is Gushers N’ Cream x Garlicane. The complex flavor is garlicky, musky, peppery, and creamy, with some diesel for good measure. If you and your friends are able to finish this, prepare for a night with nothing to do but relax. They sell for $40 to $45. Credit: Steve NeavlingCherry Zest #4 flower and Strawberry Guava #9 by 710 Labs: Noodle Doinks, as 710 Labs calls them, are an indulgence, but they’re a fun way to celebrate a birthday, ring in the new year, or enjoy other meaningful moments. With 1.5 grams of flower and 0.5 grams of rosin, Noodle Doinks pack a strong punch and are extra flavorful. My favorite is Cherry Zest #4 flower and Strawberry Guava #9, and it tastes just like its name suggests. This one provides some energy and euphoria for a daytime adventure or an adventurous night out with friends. They go for about $50. Credit: Steve NeavlingConfetti by Ice Kream Hash: If you want a more inexpensive option that still hits hard and is smaller, Ice Kream Hash has you covered with these miniature rosin-infused prerolls. At .5 grams each, these are a combination of flower and rosin. But don’t let their size fool you. They are potent. These little guys are priced at about $9 each or $25 for a pack of three. Credit: Steve Neavling
President Donald Trump signed an executive order on Thursday relaxing cannabis’ classification in a change that is expected to catalyze investment and spark new innovation in an industry that’s waited decades for the very decision.
Trump’s executive order reschedules cannabis from Schedule I—a status it’s held for decades alongside heroin and LSD—to Schedule III, or substances like ketamine and certain steroids that are recognized for having medical benefits alongside a potential for abuse..
To be clear, the executive order does not legalize cannabis, which remains illegal at the federal level. “I want to emphasize that the order I am about to sign doesn’t legalize marijuana in any way, shape, or form,” Trump said on Thursday. “In no way it sanctions its use as a recreational drug – it has nothing to do with it – just as prescription painkillers may have legitimate uses, but can also do irreversible damage.”
The president also greenlit a program that will reimburse Medicare patients who use products containing CBD, a compound derived from cannabis plants without the psychoactive component responsible for intoxication.
An Inc.com Featured Presentation
The move also opens up new opportunities in medical research since it’s far easier to conduct clinical trials on Schedule III substances compared to Schedule I drugs. The decision is also expected to expand cannabis businesses’ access to banking services in states where the substance is legal.
“We’re grateful to President Trump for recognizing the overwhelming majority of Americans who support cannabis rescheduling, opening the door to federal reform, medical research, and normalization for an industry that employs hundreds of thousands of professionals and contributes billions of dollars in taxes and economic activity every year,” says George Archos, the founder and CEO of Verano, a cannabis company.
Cannabis companies will also no longer face a part of the tax code known as Section 280E, which bars companies working with controlled substances from receiving tax credits or deductions. Section 280E specifically applies to Schedule I and Schedule II substances, so cannabis companies could save up to millions in taxes, according to past estimates from Vicente LLP, a law firm.
The Biden administration floated the decision to reclassify cannabis last year, but those efforts ultimately stagnated. And it’s a decision that doesn’t have support among all Republican lawmakers. Still, reclassification is a decision that has grown in popularity amongst Americans, particularly younger ones. A Pew Research study demonstrates that a majority of consumers under 30 back legalizing cannabis for medical and recreational use.
Who is Rep Andy Harris and why does he hate cannabis, his role in blocking rescheduling and shaping federal marijuana policy debates.
While the marijuana industry holds its breath on whether the President will finally take long promised action, a new foe has emerged. Who is Rep Andy Harris and why does he hate cannabis. Harris (R-Md.) is a physician-turned-congressman who has represented Maryland’s 1st District since 2011. A staunch social and fiscal conservative, Harris has made a name for himself as a showdown-willing member of the House Freedom Caucus and one of Congress’s most vocal opponents of loosening federal marijuana rules.
His opposition has become especially visible as the federal government weighs reclassifying cannabis under the Controlled Substances Act. Harris has repeatedly pushed back against rescheduling, arguing the change would be a public-health mistake even if it helped his party politically — famously telling reporters he “doesn’t care whether it’s good for the party or not” and his personal beliefs drive his position. He has used his medical credentials and committee access to press the DEA and Justice Department to reconsider or slow any move to move cannabis out of Schedule I.
His stance has put Harris at odds with many in both parties who frame rescheduling as modest administrative relief — a shift to would mainly ease research barriers and allow ordinary tax deductions for state-legal businesses rather than instant national legalization. Harris has been among the Republicans publicly urging caution and in some cases urging rollback, saying he would prioritize what he sees as public safety over political convenience even if the president favors change.
Beyond cannabis, Harris has a long record of blocking or resisting measures on several fronts. In the Maryland Senate he led a lengthy filibuster against anti-discrimination protections for same-sex couples; in Congress he’s pushed amendments to limit federal funding for wind-farm projects, opposed mask and lockdown policies during COVID-19, promoted unproven treatments early in the pandemic, and used appropriations levers to press social-policy goals. As Freedom Caucus chair, he’s also been a key dissident voice on spending and budget negotiations, at times voting “present” or leading objections making compromise more fraught.
What the combination means politically is straightforward: Harris is less a moderating institutionalist and more an ideological gatekeeper. When the nation debates incremental steps on cannabis policy — rescheduling which could ease research, banking and taxes for state legal businesses — he’s been a high-profile obstacle. For advocates and entrepreneurs who say rescheduling would relieve tax and regulatory burdens on thousands of small, mom-and-pop cannabis operators, Harris’s resistance signals administrative changes alone may not be enough; legislative and political fights will persist.
Whether Harris’s position will bend depends on the balance of power in Congress and the White House. For now, his mix of medical credentials, social conservatism and Freedom Caucus influence makes him one of the most consequential critics of any federal move to ease cannabis restrictions — and a reminder rescheduling debates are as much political theatre as they are technical.
